首页> 外国专利> USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS

USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS

机译:使用ENTPD3进行鉴定,分离和增强成熟干细胞衍生的胰岛素产生细胞

摘要

Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.
机译:本文公开了用于提高β-细胞(β-细胞)的疗法的有效性的方法,系统和组合物。本文还公开了与鉴定,分类和分离干细胞源性胰腺β细胞(SBC)的异质群体的方法,系统和组合物,进入更有用且功能均匀的细胞群。在许多实施方案中,使用细胞表面蛋白质胞外核苷三磷酸二磷酸二磷酸酶-3(ENTP3)来鉴定和活的SBC的最成熟和活性,其也称为CD39L3。目前公开的方法,系统和组合物可用于细胞疗法,例如替代疗法。在许多实施方案中,所公开的系统,方法和组合物可用于治疗糖尿病。在一些实施方案中,所公开的方法,系统和组合物可用于治疗,预防和/或固化糖尿病,例如1型糖尿病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号